NIH details for data safety monitoring plan (2016)

Located At: NIH guidance for 424, forms D, Section II, 4.1.5 “Data and Safety Monitoring Plan”

The NIH Data and Safety Monitoring Policy is described and referenced in Part II Section 5.3.

If the proposed research includes a clinical trial (See definition of “clinical trial” under Part III Section 3), create a document entitled “Data and Safety Monitoring Plan.” For all clinical trials, NIH requires a data and safety monitoring plan (DSMP) that is commensurate with the risks of the trial and its size and complexity. In this attachment, you must provide a description of the DSMP that you are proposing to establish for each clinical trial proposed, including:

  • The overall framework for safety monitoring and what information will be monitored.
  • The frequency of monitoring, including any plans for interim analysis and stopping rules (if applicable).
  • The process by which Adverse Events (AEs), including Serious Adverse Events (SAEs) such as deaths,hospitalizations, and life threatening events and Unanticipated Problems (UPs), will be managed and reported as required to the Institutional Review Board (IRB), the person or group responsible for monitoring, the funding IC, the NIH Office of Biotechnology Activities (OBA;http://osp.od.nih.gov/office-biotechnology-activities/biosafety/nih-guidelines), and the Food and DrugAdministration (FDA; http://www.fda.gov/).
  • The individual(s) or group that will be responsible for trial monitoring and advising the appointing entity. Because the monitoring plan will depend on potential risks, complexity, and the nature of the trial, a number of options for monitoring are possible. These include, but are not limited to, monitoring by a: §PD/PI: While the PD/PI must ensure that the trial is conducted according to the protocol, in some cases (e.g., low risk trials, not blinded), it may be acceptable for the PD/PI to also be responsible for carrying out the DSMP. (some option below)
    • Independent safety monitor/Designated medical monitor: a physician or other expert who isindependent of the study.
    • Independent Monitoring Committee or Safety Monitoring Committee: A small group ofindependent investigators and biostatisticians.
    • Data and Safety Monitoring Board (DSMB): a formal independent board of experts includinginvestigators and biostatisticians. As noted in Part II Section 5.3, NIH requires the establishmentof DSMBs for multi-site clinical trials involving interventions that entail potential risk to the

Supplemental Grant Application Instructions II-11

participants, and generally for Phase III clinical trials. Although Phase I and Phase II clinical trials may also need DSMBs, smaller clinical trials may not require this oversight format, and alternative monitoring plans may be appropriate. •If a DSMB is used, please describe the general composition of the Boardwithout naming specific individuals.

 

 

how to clear apostrophes from ranges in excel worksheets

To clear the cells, I clicked the area between cell A, and 1 to highlight all of the cells. Afterwards, I went to Home–>Clear—>Clear format to remove the apostrophe.

 To edit/fix the cells, I selected the last group,i.e. BX to highlight all of the cells in that column. Then, I dragged the arrow to the left to get all of the other cells highlighted. Afterwards, I clicked the error button to convert the text to numbers.

Authentication of Key Biological and/or Chemical Resources, Forms D

If applicable to the proposed science, briefly describe methods to ensure the identity and validity of key biological and/or chemical resources used in the proposed studies. No more than one page is suggested.
l
Key biological and/or chemical resources may or may not be generated with NIH funds and: 1) may differ from laboratory to laboratory or over time; 2) may have qualities and/or qualifications that could influence the research data; and 3) are integral to the proposed research. These include, but are not limited to, cell lines, specialty chemicals, antibodies, and other biologics.
l
Standard laboratory reagents that are not expected to vary do not need to be included in the plan. Examples are buffers and other common biologicals or chemicals.
Reviewers will assess the information provided in this Section. Any reviewer questions associated with key biological and/or chemical resource authentication will need to be addressed prior to award.
Applications identified as non-compliant with this limitation will be withdrawn from the review process (see NOT-OD-15-095 and NOT-OD-16-011).